The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine

Optimal two-stage designs for phase II clinical trials

Richard Simon · Controlled Clinical Trials · 1989 · 3.6K citations

Public Health, Biostatistics, Experimental Design +10

Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski et al. · Journal of Clinical Oncology · 2003 · 3.1K citations

Medicine, Oncology, Pharmacology +13

Antitumor Activity of Thalidomide in Refractory Multiple Myeloma

Seema Singhal, Jayesh Mehta, Raman Desikan et al. · New England Journal of Medicine · 1999 · 2.6K citations · Full text

Medicine, Hematology, Oncology +14

Thalidomide is an inhibitor of angiogenesis.

Robert J. D’Amato, Michael Loughnan, Evelyn Flynn et al. · Proceedings of the National Academy of Sciences · 1994 · 2.5K citations

Medicine, Pharmacology, Pharmacotherapy +14

Modified RECIST criteria for assessment of response in malignant pleural mesothelioma

Michael Byrne, Anna K. Nowak · Annals of Oncology · 2004 · 646 citations · Full text

Medicine, Oncology, Thoracic Oncology +9